Bristol-Myers Squibb vs Vertex Pharmaceuticals
Bristol-Myers Squibb (BMY), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Vertex Pharmaceuticals is worth $135.1B on the stock market and Bristol-Myers Squibb $124.7B: Vertex Pharmaceuticals is valued at 8% more. Bristol-Myers Squibb trades at 13.5 times earnings and Vertex Pharmaceuticals at 34.3. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Vertex Pharmaceuticals's +23.5%.
Key facts
- Bristol-Myers Squibb market value
- $124.7B
- Vertex Pharmaceuticals market value
- $135.1B
- Bristol-Myers Squibb P/E
- 13.5
- Vertex Pharmaceuticals P/E
- 34.3
- Bristol-Myers Squibb revenue
- $48.2BFY to 2025-12-31
- Vertex Pharmaceuticals revenue
- $12BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Bristol-Myers Squibb | Vertex Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $124.7Blower | $135.1Bhigher |
| Revenue | $48.2Bhigher | $12Blower |
| Earnings | $7.1Bhigher | $4Blower |
| Employees | 32,500higher | 6,400lower |
| Total assets | $90Bhigher | $25.6Blower |
| Valuation | ||
| P/E | 13.5lower | 34.3higher |
| P/S | 2.6lower | 11.3higher |
| P/B | 5.3lower | 6.5higher |
| Dividend yield | 4.00%higher | 0.00%lower |
| Profitability | ||
| Operating margin | — | 34.8% |
| Balance sheet | ||
| Net assets | $18.5Blower | $18.7Bhigher |
| Total liabilities | $71.5Bhigher | $7Blower |
| Total debt | $45.1B | — |
| Cash on hand | $10.2Bhigher | $5.1Blower |
| Price change | ||
| Today | -3.08%lower | -0.91%higher |
| 1 year | +33.7%higher | +23.5%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Tweedy, Browne team0.2% / 1.1%
Bristol-Myers Squibb only (14)
- Richard Pzena2.6%
- Thomas Kahn1.6%
- Josef Lakonishok1.1%
- Primecap team1.0%
- Bill Miller (founder)0.9%
- Cliff Asness0.6%
- Mark Boyar0.5%
- John Rogers0.4%
- John Overdeck and David Siegel (founders)0.4%
- Jeremy Grantham (co-founder)0.1%
- Murray Stahl<0.1%
- Mairs & Power team<0.1%
- Rajiv Jain<0.1%
- Sarah Ketterer<0.1%
Vertex Pharmaceuticals only (4)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Vertex Pharmaceuticals). Who owns BMY · Who owns VRTX
More on Bristol-Myers Squibb
Further comparisons
Bristol-Myers Squibb against its closest peers
Vertex Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Bristol-Myers Squibb or Vertex Pharmaceuticals?
By market value, Vertex Pharmaceuticals is the larger: $135.1B against $124.7B for Bristol-Myers Squibb. By revenue in its latest fiscal year, Bristol-Myers Squibb is the larger: $48.2B against $12B for Vertex Pharmaceuticals.
Which has the higher P/E ratio?
Vertex Pharmaceuticals: 34.3, against 13.5 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher dividend yield?
Bristol-Myers Squibb: 4.00%, against 0.00% for Vertex Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Bristol-Myers Squibb and Vertex Pharmaceuticals?
In their latest 13F filings, Tweedy, Browne team holds both.
Cite this page
Funkfolio, “Bristol-Myers Squibb vs Vertex Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/bmy-vs-vrtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.